Prioritization of ocular indications for a novel gene editing platform
by | February 06, 2020
The team will utilize primary and secondary research to evaluate the landscape for different disease indications based on i) current unmet needs, ii) therapeutic modes of action, iii) technical challenges of development, and iv) clinical considerations. Additionally, the team will identify interested clinical partners for developing therapies and assemble a searchable database that aggregates publicly available information on genetic diseases. The BCBA team will construct a slide deck summarizing their findings and provide recommendations to guide the client’s business strategy. Throughout the project, team members will interact directly with the company’s CEO and founder, the Chief Business Officer, an industry mentor, and Biotech Connection – Bay Area leadership.The company is growing rapidly and seeking to expand its team. Therefore, this project may result in employment opportunities for qualified BCBA team members with relevant expertise.
Project Timeline: March-May 2020, 12 weeks
Keywords: eye disease, gene editing, genetic diseases
Eligibility requirements:
- Applicants must be graduate or professional students (PhD, MD, etc.), postdoc, clinical resident or recent graduate in the Bay Area.
- Time commitment is expected to be 10-15 hrs/wk, and is volunteer based (unpaid).
Preferred Qualifications
- Preference will be given to candidates with experience in genetics, gene editing, molecular biology, vision science, ophthalmology, bioinformatics, data science, and other related fields.
- Prior experience in consulting, market research, intellectual property, entrepreneurship, business development, or industry is a plus, but not required.
To Apply:
- Submit your resume and cover letter here: http://bit.ly/
OcularIndications2020 - Application Deadline: Thursday, February 20, 2020